Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis

Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis

Abstract Background The novel sodium-glucose co-transporter 2 inhibitor (SGLT2i) potentially ameliorates heart failure and reduces cardiac arrhythmia. Cardiac fibrosis plays a pivotal role in the pathophysiology of HF and atrial myopathy, but the effect of SGLT2i on fibrogenesis remains to be elucid...

Full description

Bibliographic Details
Main Authors: Cheng-Chih Chung, Yung-Kuo Lin, Yao-Chang Chen, Yu-Hsun Kao, Yung-Hsin Yeh, Nguyen Ngoc Trang, Yi-Jen Chen
Format: Article
Language:English
Published: BMC 2023-02-01
Series:Cardiovascular Diabetology
Subjects:
Fibroblasts
Fibrosis
Empagliflozin
Sodium-glucose co-transporter 2
Calcium
Sodium-Hydrogen exchanger
Online Access:https://doi.org/10.1186/s12933-023-01756-0

Internet

https://doi.org/10.1186/s12933-023-01756-0

Similar Items